NCT01582165

Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance

Microvascular Resistance in Women With Chest Pain and no or Minimal Coronary Artery Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: Female
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Female patients presenting with persistent chest pain despite no obstructive coronary artery disease have impaired prognosis. Stress tests are often positive or inconclusive. As much as 20% of women with chest pain and minimal angiographic CAD have evidence of myocardial ischemia, suggesting impaired coronary microcirculation. The index of microvascular resistance (IMR) is a method for indirectly investigating microvascular function in the cardiac catheterization laboratory. 66 female patients, age 30-70 years, with chest pain and "normal" or near normal coronary angiograms will be included. After coronary physiologic evaluation, patients will be randomized in a double blind study to rosuvastatin 20 mg/day or matching placebo tablets for altogether 6 months. The investigators hypothesize that: 1. A substantial number of women with chest pain and normal or minimal pathology on angiograms have microvascular dysfunction defined by a raised IMR. 2. Statins, based on its pleiotropic action will improve endothelial function and thereby IMR.

Conditions

• Angina Pectoris

Interventions

Type	Name	Description
DRUG	Rosuvastatin	Rosuvastatin 20 mg once daily vs placebo for 6 months
DRUG	Placebo.	Placebo once daily vs rosuvastatin for 6 months

Timeline

• Start date: 2012-06-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2012-04-20
• Last updated: 2016-09-27

Locations

1 site across 1 country: Norway